Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence

REFERENCES

• Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2014.
   Google Scholar
• National Center for Injury Prevention and Control, CDC. Web-based Injury Statistics Query and Reporting System (WISQARS). 2014. Available at: . http://www.cdc.gov/injury/wisqars/fatal.html. . Published 2014. Accessed November 5, 2014.
   Google Scholar
• Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011; 12:657–667.
   PubMed Web of Science ®Google Scholar
• Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Depend. 2001; 61:195–206.
   PubMed Web of Science ®Google Scholar
• Lynch FL, McCarty D, Mertens J, et al. Costs of care for persons with opioid dependence in commercial integrated health systems. Addict Sci Clin Pract. 2014; 9:1–7.
   Google Scholar
• Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011; 377:1506–1513.
   PubMed Web of Science ®Google Scholar
• Rappaport R. Overview of the September 16, 2010 PDAC Meeting to Discuss Efficacy Supplement to NDA 21-897 for Vivitrol (naltrexone for extended-release injectable suspension) for prevention of relapse in recently-detoxified opioid dependent patients [Memorandum]. Available at: http://www.fda.gov/downloads/Advi-soryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/ucm225655.pdf. . Published 2010. Accessed November 5, 2014.
   Google Scholar
• McCarty D, Perrin NA, Green CA, Polen MR, Leo MC, Lynch F. Methadone maintenance and the cost and utilization of health care among individuals dependent on opioids in a commercial health plan. Drug Alcohol Depend. 2010; 111:235–240.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;(3): CD00220.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med. 2014; 370:2063–2066.
   PubMed Web of Science ®Google Scholar
• Drug Addiction Treatment Act of 2000 (DATA 2000), Title XXXV, Section 3502. Available at: http://buprenorphine.samhsa.gov/data.html.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. An introduction to Extended-Release Injectable Naltrexone for the Treatment of People With Opioid Dependence. Advisory. 2012; 11(1).. Available at: https://store.samhsa.gov/shin/content/SMA12-4682/SMA12-4682.pdf
   Google Scholar
• Ling W, Mooney L, Wu LT. Advances in opioid antagonist treatment for opioid addiction. Psychiatr Clin North Am. 2012; 35:297–308.
   PubMed Web of Science ®Google Scholar
• Lobmaier P, Kornor H, Kunoe N, Bjorndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev. 2008;(2): CD006140.
   PubMed Web of Science ®Google Scholar
• Baser O, Chalk M, Fiellin DA, et al. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011; 17:S235–48.
   PubMedGoogle Scholar
• Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2): CD002207.
   PubMed Web of Science ®Google Scholar
• Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2006;(1): CD001333.
   PubMed Web of Science ®Google Scholar
• Fareed A, Vayalapalli S, Casarella J, Drexler K. Treatment outcome for flexible dosing buprenorphine maintenance treatment. Am J Drug Alcohol Abuse. 2012; 38:155–160.
   PubMed Web of Science ®Google Scholar
• Bao YP, Liu ZM, Epstein DH, Du C, Shi J, Lu L. A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse. 2009; 35:28–33.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. NICE Technology Guidance: Methadone and Buprenorphine for the Management of Opioid Dependence [TA114]. London: National Institute for Health and Clinical Excellence; 2007. Available at: http://www.nice.org.uk/guidance/TA114/chapter/1-Guidance. . Accessed November 5, 2014.
   Google Scholar
• Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction. 2011; 106:32–51.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva: World Health Organization; 2009. Available at: http://www.who.int/substance_abuse/publications/opioid_dependence_guidelines.pdf. . Accessed November 5, 2014.
   Google Scholar
• Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006; 63:210–218.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Sullivan MA, Glass A, et al. A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. J Subst Abuse Treat. 2014; 46:546–552.
   PubMed Web of Science ®Google Scholar
• French MT, Zavala SK, McCollister KE, Waldron HB, Turner CW, Ozechowski TJ. Cost-effectiveness analysis of four interventions for adolescents with a substance use disorder. J Subst Abuse Treat. 2008; 34:272–281.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Naltrexone for Extended-Release Injectable Suspension for Treatment of Alcohol Dependence. Advisory. 2007; 6(1). . Available at: https://store.samhsa.gov/shin/content/SMA07-4267/SMA07-4267.pdf
   Google Scholar
• Hall S, Lightwood J, Humfleet G, Bostrom A, Reus V, Muñoz R. Cost-effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation. J Behav Health Serv Res. 2005; 32:381–392.
   PubMed Web of Science ®Google Scholar
• Mark T, Levit K, Buck J, Coffey R, Vandivort-Warren R. Mental health treatment expenditure trends, 1986–2003. Psychiatr Serv. 2007; 58:1041–1048.
   PubMed Web of Science ®Google Scholar
• Buck JA. The looming expansion and transformation of public substance abuse treatment under the Affordable Care Act. Health Affair. 2011; 30:1402–1410.
   Web of Science ®Google Scholar
• Humphreys K, Wagner TH, Gage M. If substance use disorder treatment more than offsets its costs, why don't more medical centers want to provide it? A budget impact analysis in the Veterans Health Administration. J Subst Abuse Treat. 2011; 41:243–251.
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep. 2010; 12:448–453.
   PubMedGoogle Scholar
• Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend. 2003; 71:295–302.
   PubMed Web of Science ®Google Scholar
• Harris AH, Gospodarevskaya E, Ritter AJ. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics. 2005; 23:77–91.
   PubMed Web of Science ®Google Scholar